Pacific Cancer Medical Center | Anaheim, CA

Research site
1801 W Romneya Drive #203, Anaheim, California, United States of America
Site insights

Top conditions

Lung Cancer (13 trials)

Non-Small-Cell Lung Carcinoma (11 trials)

Breast Cancer (10 trials)

Leukemia (6 trials)

BCR-ABL Positive Chronic Myelogenous Leukemia (5 trials)

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


22 of 57
Status: Active
Trial type: Interventional
Funder type: Industry

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

CLN-081-101 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with NSCLC (non-small cell lung cancer) harboring EGFR (epidermal g...

EGFR Exon 20 Mutation
Non Small Cell Lung Cancer
Drug: CLN-081

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Dexamethasone Mouth Rinse
Drug: LHRH Agonist

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 ye...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Ixazomib

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib
Locations recently updated

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive...

Colorectal Neoplasms
Drug: oxaliplatin
Drug: cetuximab

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting
Part 2:B-cell Malignancies
Part 1:r/r B-cell Malignancies
Drug: Orelabrutinib (ICP-022)

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to...

Chemotherapy-induced Nausea and Vomiting
Drug: IV Palonosetron 0.25 mg
Drug: Palonosetron HCl Buccal Film 0.5 mg

Brief Summary:The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFie...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Breast Cancer
Drug: Alpelisib
Drug: Fulvestrant

The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when admini...

Breast Cancer
Drug: Docetaxel
Biological: Eflapegrastim

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regim...

Active, not recruiting
Head and Neck Cancer
Drug: Pembrolizumab
Drug: 5-Fluorouracil

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer...

Castration Resistant Prostate Cancer (CRPC)
Follicular Lymphoma (FL)
Drug: PF-06821497

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metast...

Active, not recruiting
Metastatic Nonsquamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer
Drug: nab-Paclitaxel
Drug: Paclitaxel

A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer in providing pr...

Active, not recruiting
Chemotherapy-related Diarrhea
Cancer Therapy-Related Diarrhea
Drug: Placebo
Drug: Crofelemer 125 MG [Mytesi]

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safe...

KRAS/NRAS Mutation
Metastatic Colorectal Cancer

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irino...

Active, not recruiting
Metastatic Colorectal Cancer
Colorectal Cancer
Drug: Bevacizumab
Drug: Onvansertib

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting
Chemotherapy-induced Thrombocytopenia
Other: Placebo
Biological: Romiplostim

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or br...

Chemotherapy-induced Thrombocytopenia
Drug: Romiplostim
Drug: Placebo

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Active, not recruiting
Loss of Appetite
Non-small Cell Lung Cancer
Drug: Placebo for ponsegromab
Drug: ponsegromab

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Active, not recruiting
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Drug: Docetaxel
Drug: AMG 510

Trial sponsors

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS) (5 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems